---
title: "Amgen's autoimmune drug succeeds in late-stage trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299770733.md"
datetime: "2026-09-22T13:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299770733.md)
  - [en](https://longbridge.com/en/news/299770733.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299770733.md)
generator: "portal-rs"
---

# Amgen's autoimmune drug succeeds in late-stage trial

Sept 22 (Reuters) - Amgen (AMGN.O) said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body’s moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.

Here are some details:

-   The drug dazodalibep showed statistically significant and clinically meaningful improvement in patients with Sjogren’s disease at week 48.
-   Sjogren’s disease can cause extensive dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain.
-   It affects about 1% of the global population and predominantly affects women, according to the National Institutes of Health.
-   Amgen said most adverse events in the trial were mild to moderate, with few patients discontinuing treatment.
-   Novartis (NOVN.S) and Johnson & Johnson (JNJ.N) are also developing drugs to treat Sjogren’s disease, which has no approved treatments in the US.
-   Amgen plans to present detailed data from the trial at an upcoming medical meeting. The trial is expected to be completed in the fourth quarter of 2026.

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story](https://longbridge.com/en/news/300175029.md)
- [Amgen reports a Phase 3 win with Sjögren’s drug candidate](https://longbridge.com/en/news/300046755.md)
- [Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data](https://longbridge.com/en/news/299801248.md)
- [Amgen Announces Positive Topline Phase 3 Results For Dazodalibep In Sjogren's Disease](https://longbridge.com/en/news/299775087.md)
- [What's Going On With Amgen Stock Tuesday?](https://longbridge.com/en/news/298350093.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**